{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:03:29Z","timestamp":1780470209676,"version":"3.54.1"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Non-criteria antiphospholipid antibodies (aPLs) may be associated with adverse obstetric outcomes in patients who do not meet conventional antiphospholipid syndrome (APS) classification criteria. Their clinical relevance in fetal growth restriction (FGR) remains incompletely defined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study included 104 pregnant women with FGR or related adverse obstetric presentations who underwent comprehensive testing for 26 solid-phase aPL markers, together with lupus anticoagulant assessment. Criteria-aPL positivity was defined as positivity for lupus anticoagulant, anticardiolipin IgG\/IgM, or anti-\u03b22-glycoprotein I IgG\/IgM. IgA aCL and IgA anti-\u03b22GPI were measured as exploratory markers but were not included in criteria-aPL classification. Patients were categorized according to criteria and non-criteria aPL status. Hierarchical clustering was performed using the 26 solid-phase aPL markers. Continuous outcomes were compared using Kruskal\u2013Wallis or Wilcoxon rank-sum tests, and categorical outcomes using Fisher\u2019s exact test. Birth-weight analyses were restricted to live births. Treatment status was assessed using Fisher\u2019s exact test with Haldane\u2013Anscombe correction for odds ratio estimation when appropriate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among live births, gestational age at delivery and birth weight differed significantly across antibody-profile groups. Patients positive for both criteria and non-criteria aPLs had the lowest median gestational age and birth weight, 36.43 weeks (IQR, 34.57\u201338.00) and 2.15\u00a0kg (IQR, 1.88\u20132.55), respectively. The overall differences were significant for gestational age and birth weight, with p values of 0.010 and 0.007. Hierarchical clustering identified three aPL phenotypes with significant differences in gestational age and birth weight among live births, with p values of 0.011 and 0.018, respectively. In the criteria-aPL-negative and chromosomally normal subgroup, non-criteria aPL positivity was mainly driven by IgM aPE, IgM aPS\/PT, and aANXA5. Treatment status was strongly associated with pregnancy outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Comprehensive profiling of non-criteria aPLs may provide additional risk-stratification information in pregnancies complicated by FGR, particularly among patients negative for conventional criteria aPLs. These findings require validation in larger prospective cohorts with standardized antibody testing and treatment protocols.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1845168","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:06:56Z","timestamp":1780466816000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Comprehensive antiphospholipid antibody profiling and unsupervised immune phenotyping in fetal growth restriction"],"prefix":"10.3389","volume":"17","author":[{"given":"Siyin","family":"Li","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Immunology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China","place":["Mianyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofang","family":"Shu","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China","place":["Mianyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China","place":["Mianyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinmei","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China","place":["Mianyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, The Affiliated Huaian No.1 People\u2019s Hospital of Nanjing Medical University","place":["Huaian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1186\/s12884-025-07471-w","article-title":"Antiphospholipid syndrome in pregnancy: a comprehensive literature review","volume":"25","author":"Murvai","year":"2025","journal-title":"BMC Pregnancy Childbirth"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-069717","article-title":"Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management","volume":"380","author":"Knight","year":"2023","journal-title":"Bmj"},{"key":"B3","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1016\/j.medcli.2024.05.001","article-title":"Obstetric antiphospholipid syndrome","volume":"163","author":"Soto-Peleteiro","year":"2024","journal-title":"Med Clin (Barc)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/med\/9780198845096.003.0015","article-title":"Diagnostic, research, and real-life effect of the 2023 EULAR-ACR classification criteria for antiphospholipid syndrome","volume":"7","author":"Schreiber","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.221945","article-title":"Seronegative antiphospholipid syndrome: refining the value of \"non-criteria\" antibodies for diagnosis and clinical management","volume":"105","author":"Pignatelli","year":"2020","journal-title":"Haematologica"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab414","article-title":"'Non-criteria antiphospholipid antibodies': bridging the gap between seropositive and seronegative antiphospholipid syndrome","volume":"61","author":"Truglia","year":"2022","journal-title":"Rheumatol (Oxford)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s12884-026-08672-7","article-title":"The diagnostic and prognostic values of non-criteria antiphospholipid antibodies in obstetric antiphospholipid syndrome","volume":"26","author":"Han","year":"2026","journal-title":"BMC Pregnancy Childbirth"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac327","article-title":"Anti-phosphatidylserine\/prothrombin antibodies and thrombosis associate positively with HLA-DRB1*13 and negatively with HLA-DRB1*03 in SLE","volume":"62","author":"Elbagir","year":"2023","journal-title":"Rheumatol (Oxford)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.47360\/1995-4484-2024-408-417","article-title":"Thrombotic antiphospholipid syndrome: recurrent thromboses","volume":"522","author":"Reshetnyak","year":"2025","journal-title":"Dokl Biochem Biophys"},{"key":"B10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.clinbiochem.2022.12.007","article-title":"Anti-phosphatidylserine\/prothrombin complex antibodies (aPS\/PT) increase the risk for thrombosis based on lupus anticoagulant positivity","volume":"112","author":"Zhang","year":"2023","journal-title":"Clin Biochem"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jri.2024.104399","article-title":"Cross-reactivity of antigenic binding sites of antiphosphatidylserine\/prothrombin antibodies in patients with pregnancy loss and epidermal growth factor","volume":"167","author":"Aoki","year":"2025","journal-title":"J Reprod Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/aji.13890","article-title":"Correlation of anti-phosphatidylserine\/prothrombin and anti-phosphatidylserine antibodies with pregnancy outcomes","volume":"92","author":"Xiang","year":"2024","journal-title":"Am J Reprod Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.70021","article-title":"Improving diagnosis in patients with obstetric antiphospholipid syndrome through the evaluation of non-criteria antibodies","volume":"13","author":"\u00c1lvarez","year":"2024","journal-title":"Clin Transl Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jri.2024.104316","article-title":"Non-criteria and criteria antiphospholipid antibodies and their association with pregnancy outcomes in women with a history of miscarriage: A retrospective study","volume":"165","author":"Junmiao","year":"2024","journal-title":"J Reprod Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1177\/1076029620974455","article-title":"Anticardiolipin positivity is highly associated with intrauterine growth restriction in women with antiphospholipid syndrome","volume":"26","author":"Xi","year":"2020","journal-title":"Clin Appl Thromb Hemost"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.17305\/bb.2026.13546","article-title":"Annexins and autoantibodies in autoimmune diseases - Insights into SLE, APS and RA: A review","volume":"26","author":"Zhou","year":"2026","journal-title":"Biomol BioMed"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1122127","article-title":"An advanced understanding of the heterogeneous clinical features of \"non-criteria\" obstetric antiphospholipid syndrome: Two case reports and a literature review","volume":"14","author":"Peng","year":"2023","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-023-01195-x","article-title":"Cluster analysis of antiphospholipid antibodies-associated adverse pregnancy outcome patients: based on a 13-years cohort study","volume":"23","author":"Long","year":"2023","journal-title":"Clin Exp Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/nu17030555","article-title":"Fetal growth restriction and its metabolism-related long-term outcomes-underlying mechanisms and clinical implications","volume":"17","author":"Adam-Raileanu","year":"2025","journal-title":"Nutrients"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s12098-025-05653-0","article-title":"Insulin variation in insulin resistance and visfatin levels in small-for-gestational-age infants: an observational study on the gradual decline from birth to 12 months","volume":"92","author":"Chen","year":"2025","journal-title":"Indian J Pediatr"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1071\/rd11219","article-title":"Fetal growth restriction in hypothyroidism is associated with changes in proliferative activity, apoptosis and vascularisation of the placenta","volume":"24","author":"Silva","year":"2012","journal-title":"Reprod Fertil Dev"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.placenta.2024.06.019","article-title":"Criteria and non-criteria antiphospholipid autoantibodies screening in patients with late pregnancy morbidity: A cross-sectional study","volume":"154","author":"Gros","year":"2024","journal-title":"Placenta"},{"key":"B23","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/ijlh.14268","article-title":"Noncriteria antiphospholipid antibodies in antiphospholipid syndrome","volume":"46","author":"Devreese","year":"2024","journal-title":"Int J Lab Hematol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/cei\/uxae079","article-title":"Antibody profiles in the mosaic of 'seronegative' APS syndrome","volume":"218","author":"Truglia","year":"2024","journal-title":"Clin Exp Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1097\/01.ogx.0001113772.87258.ff","article-title":"Global, regional, and national stillbirths at 20 weeks' gestation or longer in 204 countries and territories, 1990-2021: findings from the Global Burden of Disease Study 2021","volume":"404","year":"2024","journal-title":"Lancet"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.967178","article-title":"Comparison of non-criteria antiphospholipid syndrome with definite antiphospholipid syndrome: A systematic review","volume":"13","author":"Pires da Rosa","year":"2022","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"67","DOI":"10.4137\/cmped.s40070","article-title":"Intrauterine growth restriction: antenatal and postnatal aspects","volume":"10","author":"Sharma","year":"2016","journal-title":"Clin Med Insights Pediatr"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1845168\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:06:58Z","timestamp":1780466818000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1845168\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":27,"alternative-id":["10.3389\/fimmu.2026.1845168"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1845168","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"article-number":"1845168"}}